3-ketoacyl-acyl carrier protein synthase III

an enzyme that specifically uses CoA thioesters rather than acyl-ACP as the primer

Also Known As:

3-ketoacyl-ACP synthase III; beta-ketoacyl-ACP synthase iii; beta-ketoacyl-acyl-carrier protein synthase III

Networked: 4 relevant articles (1 outcomes, 0 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Enzymes and Coenzymes: 1
- Enzymes: 152586
  - Transferases: 6589
    - Acyltransferases: 374
      - 3-Oxoacyl-(Acyl-Carrier-Protein) Synthase: 3
        3-ketoacyl-acyl carrier protein synthase III: 4

Experts

1.	Chen, Yadong: 1 article (04/2010)
2.	Lu, Xiaoyun: 1 article (04/2010)
3.	You, Qidong: 1 article (04/2010)
4.	Alhamadsheh, Mamoun M: 1 article (07/2008)
5.	Dickey, Sonja: 1 article (07/2008)
6.	Gergeres, Danielle A: 1 article (07/2008)
7.	Greenhalgh, Kerriann: 1 article (07/2008)
8.	Lim, Daniel: 1 article (07/2008)
9.	Ramaraju, Praveen: 1 article (07/2008)
10.	Revell, Kevin D: 1 article (07/2008)

Related Diseases

1.	Tuberculosis (Tuberculoses) 04/01/2010 - "Mycobacterium tuberculosis beta-ketoacyl-acyl carrier protein synthase III (mtFabH) has been identified as a novel target for treating tuberculosis. " 12/01/2002 - "As an example, phylogenetic and structural analyses suggest that sequence and binding-pocket conservation in FabH (beta-ketoacyl-ACP synthase III) would allow for the development of small molecule inhibitors not only effective against a broad species spectrum of community bacterial pathogens but also as potential new therapies for tuberculosis and malaria."
2.	Malaria 12/01/2002 - "As an example, phylogenetic and structural analyses suggest that sequence and binding-pocket conservation in FabH (beta-ketoacyl-ACP synthase III) would allow for the development of small molecule inhibitors not only effective against a broad species spectrum of community bacterial pathogens but also as potential new therapies for tuberculosis and malaria."
3.	Infections 08/09/2023 - "These compounds may have the potential to inhibit the beta-ketoacyl-ACP synthase III drug target and can help to combat Yersinia pestis-related infections. " 07/01/2008 - "These structurally simple disulfides have been found to inhibit beta-ketoacyl-acyl carrier protein synthase III, or FabH, a key enzyme in type II fatty acid biosynthesis, and thus may serve as new leads to the development of effective antibacterials for MRSA and anthrax infections."
4.	Anthrax 07/01/2008 - "These structurally simple disulfides have been found to inhibit beta-ketoacyl-acyl carrier protein synthase III, or FabH, a key enzyme in type II fatty acid biosynthesis, and thus may serve as new leads to the development of effective antibacterials for MRSA and anthrax infections."

Related Drugs and Biologics

1.	Fatty Acids (Saturated Fatty Acids)
2.	Enzymes
3.	Disulfides

Related Therapies and Procedures

1.	Therapeutics